Summarized by Masters of Longevity from Longevity Technology.
VectorY closed $83.5 million to fund an expanded ALS trial and brain‑disease programs.

Key Takeaways
- VectorY raised $83.5 million to fund development.
- The company is targeting pathological TDP‑43 aggregates in ALS.
- Proceeds will fund an expanded ALS trial and pipeline.



